Magnetic Sentinel Lymph Node Biopsy
The future of cancer staging
Sentinel Lymph Node Biopsy
Sentinel Lymph Node Biopsy (SLNB) has been widely accepted as the replacement for axillary lymph node dissection as the staging procedure for early node-negative breast cancer. Traditionally SLNB involves injecting radioactive drugs which are dependent on nuclear medicine availability and blue dyes that can put a patient at risk for anaphylaxis and skin necrosis.1,2
Magnetic Sentinel Lymph Node Biopsy
Magnetic SLNB uses a single tracer that offers the freedom to be injected in the operating room or up to thirty days beforehand to improve scheduling and the patient experience.
Magnetic sentinel lymph node biopsy with the sentimag® localization platform
Magtrace® Lymphatic Tracer
Engineered to be uniform and small enough for rapid migration, yet large enough to be mechanically filtered by the sentinel lymph nodes.
Sentimag® Localization Platform
Four techniques in one platform allow for more surgical options than any other non-gamma localization system.